Last updated: 2026-09-09 05:10:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
RenovoRx, Inc. (RNXT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.20, with a market capitalization of $107.86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.70 to $2.59. This page covers its latest market performance, valuation, price trends and company information.
$107.86M | |
$2.31 | |
$16.74 | |
$0.53 | |
$2.39 | |
1.19M | |
591.60K | |
-- | |
$2.59 | |
$0.70 | |
-- | |
-- |
RenovoRx, Inc. (RNXT) last closed at $2.39 as of 2026-09-08 23:54:00, unchanged from the previous close of $2.39.
During the latest regular trading session, RNXT traded between $0.53 and $16.74, with a volume of 1.19M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, RenovoRx, Inc. (RNXT) moved from $1.48 to $2.20, representing a gain of 48.38% ($0.72).
The stock traded between $1.43 and $2.59 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 2.59 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 79.1%
RNXT is currently trading at $2.20, placing it 79.1% of the way from its 52-week low of $0.70 to its 52-week high of $2.59. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of RenovoRx, Inc. (RNXT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.